Case File
efta-01374179DOJ Data Set 10OtherEFTA01374179
Date
Unknown
Source
DOJ Data Set 10
Reference
efta-01374179
Pages
1
Persons
0
Integrity
Extracted Text (OCR)
Text extracted via OCR from the original document. May contain errors from the scanning process.
AGP LP 519 Alpha Group Capital Paul Barrett
Alke° Capital Management
FvkrSson A4enklpti. 20'1' Eton(
New York, NY. 10017
Tet:
21271668010
New York I Song Kong- I Boston
Dear Investor,
Alkeon Growth Partners:
Sept. 2017
2017
Alkeon Growth
Strategy
Since Inception
(Cumulative)
Alkeon Growth
Strategy
Since Inception
(Annualized)
Alkeon Growth Partners
0.47%
26.23%
1225.84%1
13.98%1
MSCI World
2.08%
14.24%
113.60%
3.92%
MSCI AC World
1.77%
15.42%
113.66%
3.92%
Alkeon Growth Partners Portfolio information (Approximate):
•
Net Exposure (delta adjusted)
84.7%
•
Gross Exposure
195%
•
Number of Long Positions
98
•
Number of Short Positions
88
September offered positive results to global equities. Alkeon Growth Partners, LP returned 0.47%. Portfolio performance
was positive in the US and Asia and negative in Europe. Our long positions had positive performance during the month
while our short positions underperformed.
We remain equally constructive on the current global opportunity set for both long and short investments, as we see
significant sector-wide discrepancies between valuations and underlying fundamentals. As a result, we believe this is
shaping up to be one of the best stock-picking environments since the 2000-01 technology bubble and have maintained a
gross exposure at the high-end of our historical range. Furthermore, from a valuation perspective we consider many high
quality growth sectors, such as technology and healthcare, to be undervalued and attractive relative to the market.
There are three main drivers of portfolio performance so far this year, all of which we believe are likely to be persistent in
years to come and favorable to our strategy, as we have detailed in our Q2 letter. One. outperformance of international
stocks (for the first year since 2009), two, the beginning stages of valuation multiple renormalization of high quality growth
stocks vs. low-growth defensive equity investments (i.e., high quality growth sectors, such as technology and healthcare,
should ultimately trade at a premium to the market and especially to low-growth defensive sectors, such as utilities,
consumer staples and REITs), and, three, strong fundamental performance ("beat-and-raise" quarterly results) by many
high quality classic growth compounders. We believe all of these drivers are likely to persist beyond the short-term and
continue to favor our strategy going forward (for reasons we detailed in our Q2 letter). In particular, we believe the
fundamental performance of high quality classic growth compounders has the potential to not only persist but also
strengthen in light of the upcoming wave of technological innovation (dubbed by many as 'the fourth industrial
revolution"), which we believe can be broadly impactful and revolutionary in nature, similar to the internet wave of the
CONFIDENTIAL - PURSUANT TO FED. R. CRIM. P. 6(e)
CONFIDENTIAL
DB-SDNY-0068746
SDNY_GM_00214930
EFTA01374179
Forum Discussions
This document was digitized, indexed, and cross-referenced with 1,400+ persons in the Epstein files. 100% free, ad-free, and independent.
Annotations powered by Hypothesis. Select any text on this page to annotate or highlight it.